Keywords: astrazeneca, beats, forecasts, troubled, crestor, sees, 1st-qtr
AstraZeneca beats forecasts as troubled Crestor sees 1st-qtr sales double
Article | 09 May 2005
Anglo-Swedish drug major AstraZeneca beat analysts' expectations of earnings per share of $0.57 in reporting a 33% rise to $0.63, with pretax profit ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
